Skip to content

A Randomized Controlled Clinical Study on the Effect of Kidney-Tonifying and Blood-Activating Method on IVF-ET Pregnancy Outcomes of Postoperative Infertile Patients with Stage III/IV Endometriosis

Clinical Study on the Effect of Kidney-Tonifying and Blood-Activating Method on IVF-ET Pregnancy Outcomes of Postoperative Infertile Patients with Stage III/IV Endometriosis

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035252
Enrollment
Unknown
Registered
2020-08-05
Start date
2020-08-10
Completion date
Unknown
Last updated
2020-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 38 Years

Inclusion criteria

Inclusion criteria: (1) Patients who meet the above-mentioned diagnostic criteria of Chinese and Western medicine, aged 20-38 years old, have been diagnosed with stage III and IV endometriosis through laparoscopic surgery, and are planning to undergo IVF-ET for fertility at a reproductive center; (2) Have not received traditional Chinese medicine, hormones and similar treatments for at least 3 months before enrollment; (3) Be able to receive oral treatment with Chinese medicine and voluntarily cooperate with relevant inspections; (4) Informed consent to this study and signed informed consent form. (5) Receive random grouping and take drugs according to the study protocol.

Exclusion criteria

Exclusion criteria: (1) Those with genital tract malformations, uterine submucosal fibroids, and intrauterine adhesions found by hysteroscopy; (2) Patients with adenomyosis and hydrosalpinx; (3) The woman whose endocrine test is abnormal; (4) Other abnormal immune antibodies; (5) The man with severe oligospermia; (6) Those who have had immunotherapy or used immune function regulating drugs in the past 3 months; (7) Those who have a history of autoimmune diseases and/or other medical and surgical diseases; (8) Patients with cardiovascular and cerebrovascular diseases, severe primary diseases of the liver, kidney, and hematopoietic system and mental illnesses.

Design outcomes

Primary

MeasureTime frame
Live birth rate;Pregnancy rate;Clinical pregnancy rate;Embryo implantation rate;Abortion rate;

Secondary

MeasureTime frame
Serum hormone determination;Biochemical factor detection;Endometrial receptivity test;Oocyte and embryo grade evaluation;

Countries

China

Contacts

Public ContactMin Xu

Guangdong Hospital of Traditional Chinese Medicine

xumin3333@163.com+86 20-39318991

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026